Gossamer Bio, Inc.

0.51 USD
-0.01 (-1.15%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Gossamer Bio, Inc. stock is down -29.53% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 June’s closed higher than May. 100% of analysts rate it a buy.

About Gossamer Bio, Inc.

Gossamer Bio, Inc. focuses on discovering, acquiring, developing, and commercializing therapeutics in immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor. GB5121, an oral, irreversible, covalent, small. molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central. central central nervous system lymphoma.